Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the biopharmaceutical sector. This month’s column covers deals announced in August and early September.
Gene therapy biotech Voyager Therapeutics Inc. announced a pair of agreements during the week of Sept. 12 that will help advance its efforts to create adeno-associated virus-mediated gene-silencing therapies for severe central nervous system disorders such as advanced Parkinson's disease and Huntington's disease. It licensed a capsid program from the California Institute of Technology on Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?